A randomised, REQUIP IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP CR on abnormal daytime somnolence in patients with Parkinson's Disease

Trial Profile

A randomised, REQUIP IR-controlled, n-of-1, multiple crossover, pilot trial of the effect of REQUIP CR on abnormal daytime somnolence in patients with Parkinson's Disease

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Sep 2013

At a glance

  • Drugs Ropinirole (Primary)
  • Indications Parkinson's disease; Somnolence
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2011 Planned End Date changed to 10 Jun 2010.
    • 02 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top